Skip to main content

Table 1 Statistical power (1-β) of a trial comparing nitric oxide with placebo (n = 90 patients per group) for the adjunctive therapy of severe malaria, using longitudinal Ang-2 levels as primary outcome

From: Inhaled nitric oxide for the adjunctive therapy of severe malaria: Protocol for a randomized controlled trial

Standard Deviation of Ang-2 levels at admission (% of mean) Difference in rate of change of Ang-2 between groups
  30% change (810 pg/mL/day) 40% change (1080 pg/mL/day) 50% change (1350 pg/mL/day)
40 82% 97% 99%
50 66% 89% 98%
80 42% 60% 80%